The 9th International Pharmaco-Economic Collaboration on Alzheimer’s Disease (IPECAD) conference will take place on 12-13 November 2025 in Glasgow, under the theme “Health Economic Challenges for New Alzheimer’s Treatments”. Organised by Linus Jönsson (Karolinska Institutet), Ron Handels (Maastricht University and Karolinska Institutet) and Will Herring (RTI Health Solutions and Karolinska Institutet), together with Anna Hansson, Anders Wimo, Bengt Winblad and Anders Skoldunger (Karolinska Institutet), the IPECAD conference will bring together clinicians, researchers, policymakers, industry experts, and patient representatives to discuss the key health-economic challenges surrounding new Alzheimer’s therapies and how to ensure equitable and timely patient access.
The opening session focuses on the current health-economic evidence base, including systematic reviews of cost-effectiveness studies, learnings from the lecanemab appraisal, and comparative approaches to disease-modelling within cost-effectiveness analysis. Dedicated sessions will address follow-up registries for reimbursement and coverage decisions and advanced modelling of amyloid-targeting therapies, with presentations on payment models, value-based pricing and cost-effectiveness.
Further sessions will examine the cost-effectiveness of diagnostic–treatment combinations, particularly the role of blood-based and body-fluid biomarkers in enabling test-treat strategies, followed by analyses of informal care and quality of life, incorporating new methods for valuing caregiver contributions and pooled European data on resource use in dementia. The conference will conclude with a forward-looking session on system readiness and diagnostic capacity. To learn more and register for the conference, visit the IPECAD website, here: http://www.ipecad.org/
